Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established and heavily genericized. Real-world data (RWD) reveals that oral loop diuretics, beta blockers, and ACE inhibitors are the cornerstones of CHF therapy. However, Entresto, the most recent addition to the CHF armamentarium, continues to experience growing patient share. Here we explore drug-prescribing patterns in CHF and reveal the main characteristics of patients receiving the key CHF agents.

Questions answered:

  •  What is the patient share in CHF for Entresto, Corlanor, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), diuretics, nitrates, spironolactone, eplerenone, and other key drug classes?
  • What are the demographic characteristics and clinical profiles of CHF patients prescribed Entresto, Corlanor, and the key drug classes?
  • What are the key risk factors, comorbidities, and coprescribed therapies by patient segment for CHF?
  • How do patient cohorts in CHF compare in care utilization and outcomes (physician visits and other healthcare encounters)?
  • What kind of insurance and provider do CHF patients have?
  • What are the reimbursed and out-of-pocket costs for CHF therapies?

Product description:

Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive RWD repository.

Markets covered: United States

Key drugs covered: Entresto, Corlanor, BiDil, Coreg CR, Toprol XL, Lasix, beta blockers, ACE inhibitors, ARBs, diuretics, nitrates, spironolactone, eplerenone

Table of contents

  • Heart Failure - Current Treatment - Detailed, Expanded Analysis - Patient Profiler - US

Author(s): Dominika Rudnicka-Noulin, PhD, MSc

Dominika Rudnicka-Noulin, PhD, MSc is a senior business insights analyst in the Cardiovascular, Metabolic and Renal division at Decision Resources Group, specializing in cardiovascular diseases, with expertise in heart failure and acute coronary syndrome.

Prior to joining DRG, Dominika held a position of an associate editor at Nature Communications, working across a variety of therapy areas. Dominika also worked for three years as a Postdoctoral Research Associate on a joint project between Imperial College London and MedImmune aimed at developing more potent antibody-based drugs. Dominika gained her PhD at the Institut Pasteur in Paris, France where her work was funded by the European Commission Marie Skłodowska-Curie Actions


Related Reports

Heart Failure - Geographic Focus: China - Heart Failure | China In-Depth | China

Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population...

View Details

Heart Failure - Landscape & Forecast - Disease Landscape & Forecast

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacolog...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis - Chronic Heart Failure - Preserved Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophys...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis - Chronic Heart Failure - Reduced Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Drug treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF)...

View Details